Related Experiment Video
Updated: Aug 9, 2026
11:46
Investigating Protein-protein Interactions in Live Cells Using Bioluminescence Resonance Energy Transfer
Published on: May 26, 2014
Development of a BRET2 screening assay using beta-arrestin 2 mutants
Milka Vrecl1, Rasmus Jorgensen, Azra Pogacnik
1Institute of Anatomy, Histology & Embryology, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.
Journal of Biomolecular Screening
|June 12, 2004
Summary
Researchers enhanced bioluminescence resonance energy transfer (BRET(2)) signals for G-protein-coupled receptor (GPCR) interactions using modified beta-arrestin 2 (beta-arr2). Mutants deficient in clathrin-coated vesicle interaction significantly increased BRET(2) signals for class A GPCRs.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Signaling
Background:
- G-protein-coupled receptors (GPCRs) mediate cellular responses to diverse stimuli.
- Beta-arrestin 2 (beta-arr2) plays a critical role in GPCR desensitization and internalization.
- Bioluminescence resonance energy transfer (BRET(2)) is a technique used to study protein-protein interactions in living cells.
Purpose of the Study:
- To enhance the signal generated from GPCR and beta-arrestin 2 interactions measured by BRET(2) technology.
- To investigate the impact of beta-arrestin 2 phosphorylation-independent and clathrin-coated vesicle interaction-deficient mutants on BRET(2) signals.
- To assess the utility of modified beta-arrestin 2 in GPCR screening assays.
Main Methods:
- Utilized bioluminescence resonance energy transfer (BRET(2)) to measure interactions between GPCRs (class A and class B) and wild-type or mutant beta-arrestin 2.
- Employed beta-arrestin 2 phosphorylation-independent (R169E) and clathrin-coated vesicle interaction-deficient mutants (R393E, R395E, 373 stop).
- Performed agonist and antagonist screening assays using BRET(2) technology with modified beta-arrestin 2.
Main Results:
- Mutants of beta-arrestin 2 deficient in clathrin-coated vesicle interaction significantly increased BRET(2) signals (over 2-fold) for class A GPCRs (e.g., beta(2)-adrenergic receptor).
- No significant signal enhancement was observed for class B GPCRs (e.g., neurokinin-type 1 receptor) with the tested beta-arrestin 2 mutants.
- The beta-arrestin 2 R393E, R395E mutant successfully enhanced signal windows for other GPCRs (NPY2-R, TG1019) and facilitated BRET(2)-based screening.
Conclusions:
- The inability of specific beta-arrestin 2 mutants to interact with clathrin-coated vesicles likely prolongs their association with GPCRs, leading to enhanced and more stable BRET(2) signals.
- Modified beta-arrestin 2 holds potential for improving the sensitivity of BRET(2)-based assays for GPCR drug discovery.
- The findings highlight the importance of beta-arrestin 2 trafficking in modulating GPCR signaling dynamics.
